VX-445 Triple Combo Improves Lung Function in CF Patients with F508del Mutations, Phase 2 Trial Shows
cystic fibrosis, News
Adding the investigational therapy VX-445 to tezacaftor (VX-661) and Kalydeco (ivacaftor) led to a roughly 10 percent improvement in the lung function of cystic fibrosis (CF) patients with F508del mutations in the CFTR gene ... Read more